Daniel McKay
Overview
Explore the profile of Daniel McKay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
488
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Phillips C, Youssef A, Bressel M, ODay R, Sia J, McKenzie J, et al.
Ocul Oncol Pathol
. 2024 Jun;
10(2):72-79.
PMID: 38882024
Introduction: Stereotactic radiotherapy (SRT) is used for choroidal melanoma (CM) abutting the optic nerve. Visual acuity (VA) deterioration to ≤6/60 is common. We report a pilot study of reduced-dose SRT...
2.
ODay R, Conway R, Lim L, Giblin M, Cherepanoff S, Joshua A, et al.
Can J Ophthalmol
. 2024 May;
59(5):e525-e533.
PMID: 38810958
Objective: To describe the development of a web-based data collection tool to track the management and outcomes of uveal melanoma patients. Design: Description of a clinical registry. Participants: Patients with...
3.
Flanagan J, Fog L, Astrahan M, Talbot L, McKay D, Phillips C, et al.
Can J Ophthalmol
. 2024 Apr;
59(6):e775-e783.
PMID: 38582499
Objective: Ruthenium-106 brachytherapy is commonly used to treat uveal melanomas. Most centres prescribe a radiation dose to the tumour apex that is calculated with the tumour located in the centre...
4.
Flanagan J, Udovenya W, Astrahan M, McKay D, Phillips C, McKenzie J, et al.
J Contemp Brachytherapy
. 2024 Jan;
15(6):442-447.
PMID: 38230400
Purpose: Ruthenium-106 brachytherapy is a common treatment for small to medium-sized uveal melanomas. In certain clinical contexts, plaques may be placed eccentrically to tumor center. The effect of plaque decentration,...
5.
Hiong A, ODay R, Fog L, McKay D, McKenzie J, Ameratunga M, et al.
Ophthalmol Retina
. 2023 Oct;
8(4):325-330.
PMID: 37852320
Purpose: To report the effective use of neoadjuvant darovasertib and crizotinib in a patient with a large uveal melanoma (UM) in his only functional eye. Design: Case report. Subjects: One...
6.
ODay R, McKelvie P, Cherepanoff S, McKay D
Int Ophthalmol
. 2023 Mar;
43(7):2139-2141.
PMID: 36864122
No abstract available.
7.
ODay R, McKay D, McKenzie J, van Wijngaarden P
Optom Vis Sci
. 2022 Jun;
99(9):725-729.
PMID: 35678637
Significance: These cases highlight the importance of monitoring choroidal nevi with benign imaging characteristics and the potential to quantify horizontal growth using optical coherence tomography (OCT), in the absence of...
8.
Beasley A, Isaacs T, Vermeulen T, Freeman J, deSousa J, Bhikoo R, et al.
Cancers (Basel)
. 2021 Dec;
13(23).
PMID: 34885099
(1) Background: The stratification of uveal melanoma (UM) patients into prognostic groups is critical for patient management and for directing patients towards clinical trials. Current classification is based on clinicopathological...
9.
Lin V, Chung I, Toumi E, McKay D, McKenzie J, McKelvie P, et al.
Clin Exp Ophthalmol
. 2021 Oct;
50(1):50-61.
PMID: 34714583
Background: Prognostic cytological and molecular features of uveal melanoma have been well researched and are essential in management. Samples can be obtained in vivo through fine needle aspirate biopsy, vitrector...
10.
Tong A, Burch J, McKay D, Bustamante C, A Crackower M, Wu H
Nat Struct Mol Biol
. 2021 Sep;
28(10):771-772.
PMID: 34561631
No abstract available.